Jonathan Siegal Biography and Net Worth

Vice President & Corporate Controller of Vericel

Jon joined Vericel in 2021 with more than 20 years of accounting and financial leadership experience. He most recently served as Global Controller for Lantheus Medical Imaging, where he led the company’s accounting function and served as a leader across the financial organization. Prior to Lantheus, Jon served in various accounting and controllership roles of increasing responsibility across a variety of industries. Jon is a C.P.A. and earned a B.A. in Accounting and Economics from Gordon College.

What is Jonathan Siegal's net worth?: The estimated net worth of Jonathan Siegal is at least $49,651.02 as of February 5th, 2025. Mr. Siegal owns 1,206 shares of Vericel stock worth more than $49,651 as of April 21st. This net worth evaluation does not reflect any other assets that Mr. Siegal may own. Learn More about Jonathan Siegal's net worth.
How do I contact Jonathan Siegal?: The corporate mailing address for Mr. Siegal and other Vericel executives is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. Vericel can also be reached via phone at (617) 588-5555 and via email at ir@vcel.com. Learn More on Jonathan Siegal's contact information.
Has Jonathan Siegal been buying or selling shares of Vericel?: Jonathan Siegal has not been actively trading shares of Vericel over the course of the past ninety days. Most recently, Jonathan Siegal sold 1,092 shares of the business's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $61.99, for a transaction totalling $67,693.08. Following the completion of the sale, the insider now directly owns 1,206 shares of the company's stock, valued at $74,759.94. Learn More on Jonathan Siegal's trading history.
Who are Vericel's active insiders?: Vericel's insider roster includes Dominick Colangelo (President & CEO), Sean Flynn (VP), Steven Gilman (Director), Michael Halpin (COO), Jonathan Hopper (Insider), Joseph Mara, Jr. (CFO), Jonathan Siegal (Vice President & Corporate Controller), Paul Wotton (Director), and Robert Zerbe (Chairman & Director). Learn More on Vericel's active insiders.
Are insiders buying or selling shares of Vericel?: During the last year, insiders at the biotechnology company sold shares 18 times. They sold a total of 166,999 shares worth more than $7,916,453.29. The most recent insider tranaction occured on April, 10th when CEO Dominick Colangelo sold 24,850 shares worth more than $1,040,966.50. Insiders at Vericel own 7.2% of the company. Learn More about insider trades at Vericel.
Information on this page was last updated on 4/10/2025.

Jonathan Siegal Insider Trading History at Vericel

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/5/2025	Sell	1,092	$61.99	$67,693.08	1,206
1/28/2025	Sell	3,908	$61.99	$242,256.92	1,206
7/5/2024	Sell	545	$45.00	$24,525.00	1,033
10/14/2022	Sell	331	$25.47	$8,430.57	875

Jonathan Siegal Buying and Selling Activity at Vericel

Vericel Company Overview

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $40.87

$40.31

$41.75

50 Day Range

MA: $47.42

$38.60

$57.78

2 Week Range

Now: $40.87

$37.76

$63.00

Volume

532,733 shs

Average Volume

391,597 shs

Market Capitalization

$2.05 billion

P/E Ratio

681.28

Dividend Yield

N/A

Beta

1.61